Commonwealth Equity Services’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.62M Sell
16,759
-1,343
-7% -$257K ﹤0.01% 1653
2026
Q1
$3.32M Sell
18,102
-292
-2% -$53.8K ﹤0.01% 1627
2025
Q4
$3.24M Buy
18,394
+377
+2% +$61.6K ﹤0.01% 1631
2025
Q3
$2.52M Sell
18,017
-10,534
-37% -$1.42M ﹤0.01% 1827
2025
Q2
$3.59M Buy
28,551
+1,071
+4% +$133K ﹤0.01% 1566
2025
Q1
$3.76M Buy
27,480
+1,188
+5% +$170K 0.01% 1466
2024
Q4
$4.02M Sell
26,292
-2,051
-7% -$346K 0.01% 1379
2024
Q3
$5.49M Sell
28,343
-103
-0.4% -$21.5K 0.01% 1158
2024
Q2
$6.59M Buy
28,446
+6,259
+28% +$1.36M 0.01% 1031
2024
Q1
$4.78M Sell
22,187
-425
-2% -$99.5K 0.01% 1197
2023
Q4
$5.85M Sell
22,612
-804
-3% -$197K 0.01% 1017
2023
Q3
$6.02M Buy
23,416
+433
+2% +$116K 0.01% 934
2023
Q2
$6.55M Sell
22,983
-726
-3% -$216K 0.01% 888
2023
Q1
$6.59K Sell
23,709
-8,731
-27% -$2.42M 0.01% 871
2022
Q4
$8.98M Buy
32,440
+9,405
+41% +$2.66M 0.02% 668
2022
Q3
$6.15M Sell
23,035
-321
-1% -$68.2K 0.02% 793
2022
Q2
$4.76M Sell
23,356
-1,641
-7% -$335K 0.01% 929
2022
Q1
$5.26M Buy
24,997
+920
+4% +$200K 0.01% 921
2021
Q4
$5.78M Sell
24,077
-3,148
-12% -$809K 0.01% 858
2021
Q3
$7.7M Sell
27,225
-485
-2% -$159K 0.02% 664
2021
Q2
$9.6M Buy
27,710
+5,620
+25% +$1.7M 0.02% 579
2021
Q1
$6.18M Sell
22,090
-1,003
-4% -$270K 0.02% 682
2020
Q4
$5.65M Sell
23,093
-2,175
-9% -$561K 0.02% 671
2020
Q3
$7.17M Sell
25,268
-1,808
-7% -$504K 0.02% 543
2020
Q2
$7.24M Buy
27,076
+2,328
+9% +$700K 0.03% 505
2020
Q1
$7.83M Sell
24,748
-1,823
-7% -$553K 0.04% 410
2019
Q4
$7.88M Buy
26,571
+2,216
+9% +$615K 0.03% 480
2019
Q3
$5.67M Sell
24,355
-1,679
-6% -$391K 0.02% 552
2019
Q2
$6.09M Sell
26,034
-3,905
-13% -$902K 0.03% 512
2019
Q1
$7.08M Buy
29,939
+2,729
+10% +$859K 0.03% 448
2018
Q4
$8.19M Sell
27,210
-1,095
-4% -$349K 0.04% 374
2018
Q3
$10M Buy
28,305
+282
+1% +$97.1K 0.05% 348
2018
Q2
$8.13M Sell
28,023
-81
-0.3% -$22.8K 0.04% 361
2018
Q1
$7.7M Buy
28,104
+144
+0.5% +$44.7K 0.04% 357
2017
Q4
$8.91M Buy
27,960
+651
+2% +$209K 0.05% 320
2017
Q3
$8.55M Sell
27,309
-234
-0.8% -$69.3K 0.05% 308
2017
Q2
$7.47M Sell
27,543
-3,336
-11% -$882K 0.05% 324
2017
Q1
$8.44M Buy
30,879
+834
+3% +$236K 0.06% 288
2016
Q4
$8.52M Sell
30,045
-627
-2% -$186K 0.06% 274
2016
Q3
$9.6M Sell
30,672
-1,625
-5% -$481K 0.08% 236
2016
Q2
$7.81M Buy
32,297
+563
+2% +$148K 0.07% 261
2016
Q1
$8.26M Buy
31,734
+1,599
+5% +$422K 0.07% 248
2015
Q4
$9.23M Buy
30,135
+4,268
+16% +$1.23M 0.09% 222
2015
Q3
$7.55M Buy
25,867
+6,797
+36% +$2.24M 0.08% 233
2015
Q2
$7.7M Buy
19,070
+1,294
+7% +$519K 0.08% 240
2015
Q1
$7.51M Buy
17,776
+1,540
+9% +$607K 0.08% 241
2014
Q4
$5.51M Buy
16,236
+1,965
+14% +$636K 0.06% 271
2014
Q3
$4.72M Buy
14,271
+1,801
+14% +$594K 0.06% 298
2014
Q2
$3.93M Buy
12,470
+700
+6% +$211K 0.05% 340
2014
Q1
$3.6M Sell
11,770
-84
-0.7% -$26.7K 0.05% 330
2013
Q4
$3.31M Buy
11,854
+371
+3% +$96K 0.05% 332
2013
Q3
$2.77M Buy
11,483
+670
+6% +$150K 0.04% 352
2013
Q2
$2.33M Buy
+10,813
New +$2.31M 0.04% 383

Other funds holding BIIB

Commonwealth Equity Services's BIIB Position: Q2 2026 in Review

Commonwealth Equity Services reduced its Biogen (BIIB) stake by 7.4% in Q2 2026, selling an estimated $257K and leaving 16,759 shares worth $3.62M. The position accounts for ﹤0.01% of the portfolio, ranked #1653.

Commonwealth Equity Services first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $10M in Q3 2018. 362 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Commonwealth Equity Services held 16,759 shares of Biogen worth $3.62M as of Q2 2026.
  • Commonwealth Equity Services sold 1,343 Biogen shares in Q2 2026, an estimated $257K.
  • Biogen made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #1653 holding.
  • Commonwealth Equity Services first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
  • Commonwealth Equity Services's Biogen position peaked at $10M in Q3 2018.
  • 362 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.